AJPB
Issue:
Specialty Pharmacy
Volume:
5
Number:
6
Commentary
Gary M. Owens, MD
This article reviews current drug therapies for heart failure and therapy integration into a patient care framework improving patient adherence and quality of life and decreasing risk of readmission to acute care facilities.
From the Editor
Jan E. Berger, MD, MJā€”Editor-in-Chief President & CEO Health Intelligence Partners
To achieve the triple aim, the healthcare benefit and the pharmacy benefit must evolve.
Original Research
Benjamin Chastek, MS; Stuart D. Segal, MD; R. Peter Bonafede, MD; Crystal Watson, MS; Laura Becker, MS; Sandeep Chaudhari, MS; David J. Harrison, PhD; and Shravanthi R. Gandra, PhD, MBA
Among rheumatoid arthritis patients newly treated with adalimumab, etanercept, or infliximab, lower dose escalation rates and costs were seen with etanercept.
Jay Visaria, PhD, MPH; Rochelle Henderson, PhD, MPA; and Sharon Glave Frazee, PhD, MPH
The authors examined trends in the utilization of prescription opioid medication following introduction of abuse deterrent technology for Oxycontin.
Seth A. Seabury, PhD; Dana P. Goldman, PhD; and Darius N. Lakdawalla, PhD
This study characterizes the role of specialty drug utilization in aggregate private sector healthcare spending in the United States from 2000 to 2009.
Karen E. Van Nuys, PhD; Joseph J. Conoshenti Jr, BPharm, RPh, MBA; and Dana P. Goldman, PhD
This paper explores the economic incentives that oncologists face when deciding between oral and intravenous oncolytics and their impact on prescribing behavior.